Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2008

View Archived Issues

Phynova announces collaboration agreement with Norgine in liver disease

Metabolon and Joslin Diabetes Center to collaborate in area of insulin resistance and diabetes

Hemispherx enters major contract with Lovelace Respiratory Research Institute

Zacharon completes Series A Financing to advance glycan inhibitor program

Infinity enters alliance with Purdue and Mundipharma for early clinical and discovery programs

Novel tachykinin NK1 receptor antagonists divulged in recent Merck & Co. patent

Recent GSK patent claims new 5-HT1A receptor antagonists for premature ejaculation

Novel therapeutic agents for cancer cachexia and muscle wasting imparted in recent Santhera patent

Neuromed completes enrollment for phase III trial of NMED-1077 in chronic low back pain

Biofrontera completes enrollment in phase II study of BF-derm1 in severe chronic urticaria

Cosmo and Dr. Falk sign licensing agreement for Rifamycin SV MMX

Avexa completes recruitment for first component of phase III trial of apricitabine

ChemDiv and Avineuro extend collaboration in Alzheimer's disease

Johnson & Johnson enter into definitive agreement to acquire Omrix

DepoMed enters into exclusive license agreement with Solvay for DM-1796

CHMP recommends refusal of Bristol-Myers' marketing authorization for Ixempra

CHMP recommends extension to Janssen-Cilag's marketing authorization for Prezista

Bristol-Myers exercises option to develop and commercialize Exelixis' XL-413

Medarex initiates phase Ib clinical trial of MDX-1106 in cancer

Antares and Population Council initiate phase II contraceptive ATD Gel trial

MK-677 does not meet efficacy endpoints in a phase II Alzheimer's disease study

UWA-0121 extends L-DOPA activity in primate model of Parkinson's disease

Hematide safe over the long term in chronic kidney disease patients

Antiallodynic activity of Adolor's novel potent NGF-TrkA antagonist

Preliminary phase II results show activity of GI-5005-containing therapy in HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...